Precigen (PGEN) Depreciation & Amortization (CF) (2012 - 2026)
Precigen (PGEN) posted quarterly Depreciation & Amortization (CF) of $1.1 million for Q1 2026, up 74.72% year-over-year from $629000.0 in Q1 2025, and down 3.34% quarter-over-quarter from $1.1 million in Q4 2025.
Analysis
Precigen (PGEN) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 74.72% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $3.7 million (up 3.06% YoY), while the FY2025 annual figure was $3.2 million, down 29.32% from the prior year.
- Depreciation & Amortization (CF) declined to $1.1 million in Q1 2026 per PGEN's latest filing, from $1.1 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $3.3 million in Q1 2022 and bottomed at $629000.0 in Q1 2025.
- Historically, Depreciation & Amortization (CF) has averaged $1.4 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) sank 60.56% — and 2026, when it surged 74.72%.
- Precigen's Depreciation & Amortization (CF) stood at $1.7 million in 2022, then fell by 6.22% to $1.6 million in 2023, then tumbled by 59.05% to $661000.0 in 2024, then soared by 72.01% to $1.1 million in 2025, then slipped by 3.34% to $1.1 million in 2026.
- Business Quant data shows PGEN's Depreciation & Amortization (CF) at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $803000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 1.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 803,000.00 |
| Jun 30, 2025 | 630,000.00 |
| Mar 31, 2025 | 629,000.00 |
| Dec 31, 2024 | 661,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 1.72 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 1.84 Mn |
| Mar 31, 2022 | 3.29 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Sep 30, 2021 | 2.03 Mn |